The Effects Of Zhibitai Combined With Statin On Lipoprotein Profiles And Inflammatory Factors In Patients With Coronary Heart Disease And Dyslipidemia

Objectives:The aim of this study was to evaluate the lipid lowing ability, anti-inflammation effects and clinical safety of Chinese traditional medicine Zhibitai or combination use of Zhibitai and atorvastatin in pationts with coronary heart disease (CHD) and dyslipidemia, compared with atorvastatin.Methods:A total of one hundred and twenty three subjects with CHD and dyslipidemia were recruited and randomly divided into Zhibitai group (n=41), which received480mg of Zhibitai orally twice daily, Zhibitai and atorvastatin combination group (n=42),which received240mg of Zhibitai twice daily plus atorvastatin10mg daily, and atorvastatin group(n=41), which received atorvastatin20mg daily. Blood lipoproteins, myocardial enzymes, liver and renal functions were measured before treatment started, and after4and8weeks of the treatment. P-selectin and IL-6were measured before and after the treatment.Results:(1) Plasma low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and plasma triglycerides (TG) were significantly decreased after4and8weeks of treatment (p<0.05for all pairs), furthermore, Zhibitai and atorvastatin combination group is superior to atorvastatin group in lowing LDL-C both in4and8weeks(p<0.05), while high-density lipoprotein cholesterol (HDL-C) did not changed after4and8weeks of treatment (p>0.05for all pairs).(2) Inflammatory factors such as P-selectin and IL-6were significantly decreased in both groups after8weeks (p<0.01for all pairs), furthermore, Zhibitai and atorvastatin combination group is superior to atorvastatin group in lowing P-selectin and IL-6both in8weeks(p<0.05)(3) Furthermore, there was no difference in myocardial enzymes, hepatic and renal function test parameters, incidence of myopathy or gastrointestinal tract symptoms in each group. Conclusion.(1)Zhibitai therapy is a good alternative to statin therapy to reduce plasma cholesterol levels in subjects with CHD and dyslipidemia;(2) Combination use of these two drugs can further lowering LDL-C levels.(3) Combination use of these two drugs can further lowering P-selectin and IL-6levels.(4) Zhibitai and statin combination has low incident of side effect and validated clinical security, which may become a new trend for future lipid-lowing therapy.